Market closed

Ikena Oncology/IKNA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Ikena Oncology

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

Ticker

IKNA
Trading on

Industry

Pharmaceuticals

Employees

18

Ikena Oncology Metrics

BasicAdvanced
$82M
Market cap
-
P/E ratio
-$1.42
EPS
0.49
Beta
-
Dividend rate
$82M
0.49
$4.63
$1.02
50K
18.219
17.743
3.778
6.364
-27.41%
-44.54%
43.304
0.57
0.57
-1.096
-90.38%
-16.24%
-42.92%
-33.33%

What the Analysts think about Ikena Oncology

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Ikena Oncology stock.

Ikena Oncology Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Ikena Oncology Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy IKNA

$

Sign up or log in to buy
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Ikena Oncology stock?

Ikena Oncology (IKNA) has a market cap of $82M as of October 06, 2024.

What is the P/E ratio for Ikena Oncology stock?

The price to earnings (P/E) ratio for Ikena Oncology (IKNA) stock is 0 as of October 06, 2024.

Does Ikena Oncology stock pay dividends?

No, Ikena Oncology (IKNA) stock does not pay dividends to its shareholders as of October 06, 2024.

When is the next Ikena Oncology dividend payment date?

Ikena Oncology (IKNA) stock does not pay dividends to its shareholders.

What is the beta indicator for Ikena Oncology?

Ikena Oncology (IKNA) has a beta rating of 0.49. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.